Patient Engagement Strategies Include Core Compensation Principles
The International Society for Pharmacoeconomics and Outcomes Research recently published its May/July issue of its Value & Outcomes Spotlight journal [...]
ISPOR President Reflects on COVID-19 Challenges and Lasting Achievements
President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and Director and Partner at Boston Consulting Group Dr. [...]
Transitioning to Value-Based Care Requires Understanding Perceptions and Opening Up the Conversation to Diverse Stakeholders
Healthcare stakeholders hold different perceptions of value-based care, with some stakeholders associating “value” with sub-optimal care. A recent ISPOR article, [...]
Cigna’s New Shared Savings Program Offers $500 if Members Convert to Biosimilars as Billion Dollar Savings Loom
Cigna has launched a Shared Savings Program, aimed at reducing costs for its members by identifying alternative drugs offered at [...]
Upcoming ISPOR Webinar on NICE’s Modernized Data Handling Methods and 5-Year Strategy
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will hold a virtual event on July 15th at 11:00 AM [...]
Cures 2.0 Key Points Include New $6.5 Billion Federal Research Agency and Expanded RWD in Clinical Trials
Cures 2.0 was introduced on June 22nd. The proposed bipartisan legislation includes components that center on diversifying clinical trials and [...]
How Can Transparency Improve in RWD Studies?
Vice President and Global Head of Epidemiology for Johnson & Johnson Jesse Berlin shared his thoughts on real world evidence (RWE) [...]
Expanded Cures 2.0 Legislation Considers Patient Access and Broadened Use of RWD in Clinical Trials
A recent article, published by the Regulatory Affairs Professionals Society (RAPS), notes that a discussion draft meant to further the [...]
Biogen’s Aduhelm Brings Uncertainty and Concern Regarding Federal Budget
The FDA recently approved Biogen’s Aduhelm for use in patients with Alzheimer’s disease. However, its high price tag—$56,000—means that many [...]
Alzheimer’s Drug Could Equal Federal Government’s Spending on NASA
Biogen’s Aduhelm is exceedingly expensive at $56,000. If covered under Medicare, its cost could approach the federal government’s spending on [...]
HealthVerity’s IPGE Platform Overcomes RWD Challenges
Health Verity’s Identity, Privacy, Governance and Exchange (IPGE) platform takes on many of the challenges associated with real world data [...]
Register Today for Upcoming ISPOR Webinar on Using RWD to Improve Oncology Research and Patient Outcomes in China
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will host a webinar on June 29th, 2021, at 11:00 AM [...]
Biogen’s Aduhelm Unites Drug Pricing Advocates
Healthcare purchasers and employers have formed a coalition, EmployersRx, with the goal of convincing House and Senate members to enact [...]
University of Washington Professor Discusses HEOR and RWD Trends
University of Washington’s Anirban Basu discusses his thoughts on the role of real world data (RWD) in health economics and [...]
Biogen Considers Aduhelm Price Cut as Competing Alzheimer’s Drug Approved by FDA
Biogen and its partner Eisai released a statement regarding Alzheimer’s Drug Aduhelm, which is priced at $56,000 per year. The [...]
HealthVerity Webinar Highlights IPGE Platform in Processing RWD
HealthVerity’s Identity, Privacy, Governance and Exchange (IPGE) platform is streamlining the way real world data (RWD) is used to inform [...]
Is Prescription Drug Price Negotiation a Lasting Trend?
One proposed solution to high prescription drug prices is negotiating directly with manufacturers. Legislative changes allowing Medicare to carry out [...]
New ICER Webinar Series on RWD Case Studies; First Webinar on Alzheimer’s Disease Evidence Report
The Institute for Clinical and Economic Review (ICER) will begin a webinar series highlighting findings from recent draft reports and provide [...]
Researchers Identify Biased Algorithms Prevalent Throughout the US Healthcare Industry
University of Chicago researchers found that biased healthcare algorithms are affecting patient care in hospital settings, as well as interactions [...]
Register Today for Upcoming Webinar on RWD in Oncology Drug Development
A webinar on using real world data (RWD) in the context of oncology drug development will feature insight from cancer [...]
CVS Eliminates 72 Hyperinflated Drugs, Saving $1.2 Billion in 2020
CVS has removed 72 high-priced drugs from its formulary. This move has led to $1.2 billion in savings last year [...]
[Cytel Whitepaper] How Can RWE Drive Oncology Drug Development?
Cytel has published a whitepaper detailing how real world evidence (RWE) can be used in cancer drug development, from preclinical [...]
Upcoming IQVIA Webinars on Preparing for Legislative Changes and New Healthcare Trends
IQVIA is hosting a series of webinars to prepare you and your organization for policy changes, including an on-demand webinar [...]
Friday ISPOR Webinar on Value-Based Pricing
ISPOR will host a webinar on the intersection between price and value. Speakers include Omnicom’s Head of Global Health Accounts [...]
Thursday Webinar on Incorporating SDoH RWD to Improve R&D and Support Outreach Efforts
A webinar on understanding and effectively using social determinants of health (SDoH) data will take place on Friday, June 24th [...]